A New Serological Link: Autoimmune Hepatitis Connected to Viral Reactivation and Receptor Blockade
Researchers have identified a novel antibody signature specific to autoimmune hepatitis (AIH), a chronic inflammatory liver disease. Using phage-display immunoprecipitation sequencing, the team discovered antibodies against the known autoantigen SLA/LP, as well as novel reactivities to the protein DIP2A and the antifibrotic receptor RXFP1. Crucially, the DIP2A antibody target was found to cross-react with a nearly identical sequence from the U27 protein of human herpesvirus 6 (HHV6), and patients with these antibodies had higher HHV6 IgG titers, suggesting viral reactivation may be involved. Furthermore, antibodies against RXFP1 were shown to inhibit relaxin-2 signaling, potentially disrupting a natural anti-fibrotic pathway. This work provides a new mechanistic link between a common viral infection, a breakdown in immune tolerance, and the progression of autoimmune liver disease.
Why it might matter to you:
This study directly connects a viral trigger to autoimmune pathology through molecular mimicry, a core concept in host-pathogen interaction and vaccine adjuvant research. The finding that autoantibodies can functionally block a receptor involved in tissue repair (RXFP1) has clear implications for understanding immune-mediated damage in chronic inflammatory conditions, including those affecting other organ systems. For researchers exploring cell-free therapies or transplantation strategies, these insights into how the humoral immune response can directly inhibit regenerative signaling pathways could inform new therapeutic targets or diagnostic biomarkers.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
